Immunotherapy of hematological malignancies: What is new?

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Ortin M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CELL; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG SYNTHESIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS;

EID: 21344474161     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi715     Document Type: Review

References (134)

1. Beverley P. Tumour immunology. In Roitt I, Brostoff J (eds): Immunology. London: Mosby-Year Book Europe Ltd 1993; 17.
2. Falkenberg JH, Goselink HM, Van der Harst D et al. Specific lysis of clonogeneic leukaemia cells by cytotoxic T lymphocytes against minor histocompatibility antigens: An in vitro model for graft versus leukaemia. Exp Haematol 1990; 18: 682.
3. Thomas ED, Lochte HL, Wan Ching Lu, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491.
4. Mathé G, Amiel JL, Schwarzenberg L et al. Haematopoietic chimaera in man after allogeneic (homologous) bone marrow transplantation (control of secondary symptoms). Specific tolerance due to chimaerism. BMJ 1963; ii: 1633-1635.
5. Mathé G, Amiel JL. Immunotherapy: new method of treating leukaemias. Noveau Revue Francaise. Hématologique 1964; 4: 211-216.
6. Sosman JA, Sondel PM. The graft versus leukaemia effect following bone marrow transplantation: a review of laboratory and clinical data. Hematol Rev 1987; 2: 77-84.
7. Gajewski JL, Champlin RE. Enhanced graft versus leukaemia effect in patients receiving matched unrelated donor bone marrow transplants. In Champlin RE, Gale RP (eds): New Strategies in Bone Marrow Transplantation. New York: Wiley-Liss 1990; 281-284.
8. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
9. Maranchini D, Gluckman E, Blaise D et al. Impact of T cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukaemias. Lancet 1987; ii: 175-178.
10. Horowitz MM, Gale RP, Barret AJ et al. Effect of methotrexate on relapse after bone marrow transplantation for acute lymphoblastic leukaemia. Lancet 1989; i: 535-537.
11. Hagenbeek A, Lu YL, Arkesteijn GJ, et al. Minimal residual disease in acute leukaemia: preclinical studies. In Champlin RK, Gale RP (eds): New Strategies in Bone Marrow Transplantation. New York: Wiley-Liss 1990; 193-201.
12. Scott AM, Renner C. Tumour antigens recognised by antibodies. Encyclopaedia of Life Sciences. London: Nature Publishing Group, Macmillan 2001; 1-7.
13. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5: 292-302.
14. Hainsworth J. Monoclonal antibody therapy in lymphoid malignancies. Oncologist 2000; 5: 376-384.
15. Almasri N, Duque R, Iturraspe J et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259-263.
16. Byrd J, Murphy T, Howard R et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small-cell lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
17. O'Brien S, Kantarjian H, Thomas D. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
18. Hainsworth J, Litchy S, Barton J et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small-cell lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746-1751.
19. Byrd J, Petersen B, Park K et al. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia patients: results from CALGB 9712. Blood 2001; 98: 772a (Abstr 3212).
20. Wierda W, O'Brien S, Albitar M et al. Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98: 771a (Abstr 3210).
21. McLaughlin P, Grillo-Lopez J, White C et al. IDEC-C2B8 rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
22. Davis T, Grillo-Lopez AJ, White C et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkins lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18: 3135-3143.
23. Czuczman M, Grillo-Lopez A, White C et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
24. Czuczman M, Grillo-Lopez A, LoBuglio A et al. Patients with lowgrade NHL treated with rituximab and CHOP experience prolonged clinical and molecular remission. Blood 2003; 102: 411a (Abstr 1493).
25. Rambaldi A, Carlotti E, Oldani E. Quantitative PCR of bone marrow BCL2/IgH positive cells at diagnosis predicts treatment response and long-term outcome in follicular non Hodgkin's lymphoma. Blood 2005; In press.
26. Marcus R, Imrie K, Belch A et al. An international multi-centre, randomised, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular Non-Hodgkins lymphoma. Blood 2003; 102: 28a (Abstr 87).
27. Czuczman MS, Koryzna A, Mohr A et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694-704.
28. Coiffier B, Ketterer N, Haioun C et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicentre phase II study. Blood 1998; 92: 1927-1932.
29. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
30. Coiffier B, Herbrecht R, Tilly H et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with analysis according to co-morbidity factors. Proc Am Soc Clin Oncol 2003; 22: 596 (Abstr).
31. Mounier N, Briere J, Gisselbrecht C et al. Rituximab and CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
32. Howard O, Gribben J, Neuberg D et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
33. Lenz G, Dreyling M, Hoster E. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol 2005; In press.
34. Magni M, Di Nicola M, Devizz L et al. Successful in vivo purging of CD34-containing peripheral-blood harvests in mantle-cell and indolent lymphoma: evidence for a role for both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
35. Brugger W, Hirsch J, Repp R et al. Treatment of follicular and mantle-cell non-Hodgkin's lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral-blood stem-cell transplantation. Blood 2000; 96 (Suppl): 482 (Abstr).
36. Dimopoulos M, Zervas C, Zomas A et al. Treatment of Waldenstrom's macroglobulinemia. J Clin Oncol 2001; 20: 2326-2333.
37. Zinzani P, Ascani S, Piccaluga P et al. Efficacy of rituximab in hairy-cell leukemia. J Clin Oncol 2000; 15: 3875-3877.
38. Milpied N, Vasseur B, Parquet N et al. Humanised CD20 monoclonal antibody (rituximab) in post-transplant B lymphoproliferative disorder: a retrospective analysis on patients. Ann Oncol 2000; 11 (Suppl): 113.
39. Berney T, Delis S, Kato T et al. Successful treatment of posttransplantation lymphoproliferative disease with prolonged rituximab treatment in intestinal-transplant recipients. Transplantation 2002; 74: 1000-1006.
40. Hsi E, Hussein M, Elson P et al. Biologic and clinical evaluation of rituxan in the management of newly diagnosed multiple myeloma patients: an update. Proc Am Soc Clin Oncol 2001; 21: 299 (Abstr).
41. Conconi A, Thielblemont C, Martinelli G et al. An international extranodal lymphoma study group phase II study of rituximab in extranodal marginal-zone B-cell lymphomas. Proc Am Soc Clin Oncol 2001; 21: 296 (Abstr).
42. Ekstrand B, Lucas J, Horwitz et al. Rituximab in lymphocyte predominant Hodgkins disease: results of a phase II trial. Proc Am Soc Clin Oncol 2002; 21: 264 (Abstr).
43. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 768-773.
44. Kennedy S, Rawston A, Svans P et al. Campath-H1 therapy in 29 patients with refractory CLL: true complete remission is an attainable goal. Blood 1999; 94: 603a (Abstr 2684).
45. Keating M, Cazin B, Coutre S et al. Campath H1 treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen had failed. J Clin Oncol 2002; 20: 205-213.
46. Flavell DJ, Flavell SU, Boehm DA et al. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br J Cancer 1995; 72: 1373-1379.
47. Flavell DJ, Boehm DA, Emery L et al. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alonel. Int J Cancer 1995; 62: 337-344.
48. Vallera DA, Elson M, Brechbiel MW et al. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 2004; 19: 11-23.
49. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19: 176-182.
50. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-132.
51. Griffin JD, Linch D, Sabbath K et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leukemia Res 1984; 8: 521-534.
52. Dinndorf PA, Andrews RG, Benjamin D et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048-1053.
53. Jilani I, Estey E, Huh Y et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118: 560-566.
54. Press OW, Shan D, Howell-Clark J et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56: 2123-2129.
55. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198-1201.
56. Walker S, Landovitz R, Ding WD et al. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci USA 1992; 89: 4608-4612.
57. Prokop A, Wrasidlo W, Lode H et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene 2003; 22: 9107-9120.
58. Golay J, Di Gaetano N, Amico D. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 2005; 128: 310-317.
59. Sievers EL, Larson RA, Stadtmauer EA et al. for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
60. Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-1636.
61. Jedema I, Barge RM, van der Velden VH et al. Internalization and cell cycledependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004; 18: 316-325.
62. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
63. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000; 14: 474-475.
64. Walter RB, Raden BW, Cronk MR et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004; 103: 4276-4284.
65. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095-2104.
66. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310-2314.
67. Leone G, Rutella S, Voso MT et al. In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. Haematologica 2004; 89: 634-636.
68. Sivaraman S, Manjali J, Gregory SA et al. G-CSF and other cytokines modulate expression of CD33 antigen on the surface of myeloid cells. Blood 2002; 100: 554.
69. Witzig T, White C, Wiseman G et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkins lymphoma. J Clin Oncol 1999; 17: 3793-3803.
70. Witzig T, Flinn I, Gordon L et al. Treatment with ibritumomab tiuexetan radioimmunotherapy in patients with rituximabrefractory follicular NHL. J Clin Oncol 2002; 20: 3262-3269.
71. Witzig T, Gordon L, Cabanillas F et al. Randomised control trial of Yttrium 90-labelled ibritumomab tiuexetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
72. Kashyap A, Zelenetz J, Vose M et al. Tositumomab and iodine I131 tositumomab produces a meaningful therapeutic benefit for patients with relapsed, refractory and transformed low-grade NHL: summary of the long-term response population. Proc Am Soc Clin Oncol 2003; 22: 576 (Abstr).
73. Kaminski M, Estes J, Regan D et al. Front-line treatment of advanced B-cell low-grade lymphoma with radiolabelled anti-B1 antibody: initial experience. Proc Am Soc Clin Oncol 1997; 16: 15 (Abstr).
74. Dillman R. Radiolabelled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20: 3545-3557.
75. Perrault C, Decary F, Brochu S et al. Minor histocompatibility antigens - a review. Blood 1990; 76: 1269-1280.
76. Garicochea B, van Rhee F, Spencer A et al. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). Br J Haematol 1994; 88: 400-402.
77. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
78. Atra A, Millar B, Shepherd V et al. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. Br J Haematol 1997; 97: 165-168.
79. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-4343.
80. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671-3680.
81. Mavroudis DA, Read EJ, Molldrem J et al. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 1998; 21: 431-440.
82. Alessandrino EP, Bernasconi P, Caldera D et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 607-612.
83. Aker M, Kapelushnik J, Pugatsch T et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145-148.
84. Ljungren HG, Carre K. In search of the 'missing self' MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-244.
85. Pross HF. The involvement of natural killer cells in human malignant disease. In Lotzova E, Herberman RB (eds): Immunobiology of Natural Killer Cells. Boca Raton, FL: CRC Press 1986; 11-27.
86. Garssadi SI, Mandi Y, Regely K. The inhibitory effect of interpheron alpha on the serotonin-induced impairment of human NK cell activity in whole blood. Brain Behav Immun 1993; 7: 164-175.
87. Caligiuri MA, Zmuidzinas A, Manley TJ et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990; 171: 1509-1526.
88. Caliguri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91: 123-132.
89. Baume DM, Robertson MJ, Levine H et al. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 1992; 22: 1-6.
90. Ellis TM, Fisher RI. Functional heterogeneicity of Leu19 'bright' + and Leu19 'dim' + lymphokine-activated killer cells. J Immunol 1989; 142: 2949-2954.
91. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 3183-3191.
92. Robertson MJ, Manley TJ, Donahue C et al. Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol 1993; 150: 1705-1714.
93. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
94. Meropol NJ, Barresi GM, Fehninger TA et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998; 46: 318-326.
95. Cortes JE, Kantarjian HM, O'Brien S et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506-1513.
96. Lim SH, Newland AC, Kelsey S et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukemia - a phase II study. Cancer Immunol Immunother 1992; 34: 337-342.
97. Law TM, Motzer RJ, Mazumdar M. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-832.
98. Kruit WH, Goey SH, Lamers CH et al. High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cancer. J Immunother 1997; 20: 312-320.
99. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997; 80: 42-49.
100. Farag SS, Fehninger TA, Ruggeri L et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukaemia effect. Blood 2002; 100: 1935-1947.
101. Goulmy E. Class I human cytotoxic T lymphocytes directed against minor transplantation antigens and their possible role in organ transplantationClass I. Prog Allergy 1985; 36: 44-72.
102. Hauch M, Gazzola MV, Small T et al. Anti-leukaemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukaemia. Blood 1990; 75: 2250-2262.
103. Blaise D, Viens P, Olive D et al. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur Cytokine Netw 1991; 2: 121-129.
104. Richard C, Baro J, Bello-Fernandez C et al. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukaemia enhances activated killer cell function and may diminish leukemic relapse. Bone Marrow Transplant 1995; 15: 721-726.
105. Reisner Y, Martelli MF. Transplantation tolerance induced by 'mega dose' CD34+ cell transplants. Exp Hematol 2000; 28: 119-127.
106. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995; 60: 778-783.
107. Casper J, Camitta B, Truitt R et al. Unrelated bone marrow donor transplants for children with leukaemia or myelodysplasia. Blood 1995; 85: 2354-2363.
108. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
109. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
110. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
111. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 842-847.
112. Soiffer RJ, Mauch P, Tarbell NJ et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991; 7: 23-33.
113. Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872.
114. Polchi P, Lucarelli G, Galimberti M et al. Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplant 1995; 16: 529-535.
115. Kawano Y, Takaue Y, Watanabe A et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 1998; 92: 3123-3130.
116. Peters C, Matthes-Martin S, Fritsch G et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999; 13: 2070-2078.
117. Veys PA, Meral A, Hassan A et al. Haploidentical related transplants and unrelated donor transplants with T cell addback. Bone Marrow Transplant 1998; 21 (Suppl 2): S42-S44.
118. Bunjes D, Duncker C, Wiesneth M et al. CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25 (Suppl 2): S9-S11.
119. Handgretinger R, Schumm M, Lang P et al. Transplantation of megadoses of purified haploidentical stem cells. Ann NY Acad Sci 1999; 872: 351-361.
120. Ortin M, Passant M, Saul P, Darbyshire PJ. Fludarabine-based conditioning regimes for related haploidentical stem-cell transplantation. Bone Marrow Transplant 2000; 25 (Suppl 1): S34.
121. Kapelushnik J, Mandel H, Varadi G, Nagler A. Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome. J Pediatr Hematol Oncol 2000; 22: 433-436.
122. Klingebiel TE, Lang P, Schumm M et al. Current results in haploidentical stem cell transplantation in children. Bone Marrow Transplant 2000; 25 (Suppl 1): S1.
123. Ortín M, Woods P, Lawson S, Darbyshire PJ. Haploidentical stem-cell transplantation in the treatment of CD40 ligand deficiency. Int J Paediatr Haematol Oncol 2001; 7: 283-287.
124. Ortín M, Raj R, Kinning E et al. Partially matched related donor peripheral blood progenitor cells transplantation adding fludarabine and anti-lymphocyte gamma-globuline in paediatric patients. Bone Marrow Transplant 2002; 30: 359-366.
125. Ruggeri L, Capanni M, Urbani E et al. Effectivenes of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-3100.
126. Biassoni R, Cantoni C, Falco M et al. The human leukocyte antigen (HLA)-C-specific 'activatory' or 'inhibitory' natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996; 183: 645-650.
127. Colonna M, Samaridis J. Cloning of immunoglobulin superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995; 268: 405-408.
128. Vales-Gomez M, Reyburn HT, Mandelboim M et al. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 1998; 9: 337-334.
129. Vitale M, Bottino C, Sivori S et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065-2072.
130. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19: 197-223.
131. Nagler A, Brautbar C, Slavin S, Bishara A. Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity. Bone Marrow Transplant 1996; 18: 891-897.
132. Koh CY, Blazar BR, George T et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001; 97: 3132-3137.
133. Bellone G, Valiante NM, Viale O et al. Regulation of hematopoyesis in vitro by alloreactive natural killer cell clones. J Exp Med 1993; 177: 1117-1125.
134. Veys P, Amrolia P, Rao K. The role of haploidentical stem cell transplantation in the management of children with haematological disorders. Br J Haematol 2003; 123: 193-206.